Avalo Therapeutics entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) offering program. Under this arrangement, the company may issue and sell shares of its common stock from time to time at its sole discretion through Jefferies, with aggregate proceeds capped at $200 million. The company pays a commission of up to 3.0% on gross proceeds sold under this agreement. Concurrently, Avalo Therapeutics terminated its prior sales agreement with TD Securities (USA) LLC, effective immediately, ending the ability to sell shares under that previous arrangement. This filing discloses the new equity financing facility and the closure of the old one. The company operates in the biotechnology industry, focusing on the discovery and development of targeted therapies for cancer.
